0000000000815667

AUTHOR

Juan Palou

showing 9 related works from this author

Prognostic Factors And Risk Groups In T1g3 Patients Initially Treated With Bcg: Results Of A Multicenter Retrospective Series In 2530 Patients

2013

INTRODUCTION AND OBJECTIVES: The impact of prognostic factors in T1G3 patients (pts) is critical for proper treatment decision making, however most available data are from small series of pts. The aim of the current study is to assess prognostic factors in a large group of pts who received BCG as initial treatment of T1G3 tumours and identify a subgroup of high risk pts who should be considered for early cystectomy. METHODS: Individual pt data were collected for 2530 pts from 23 centers who received induction or maintenance BCG between 1990 and 2008. Using Cox regression analysis, the prognostic importance of the following variables were assessed for time to recurrence, progression to muscl…

bladder cancer T1HGSettore MED/24 - Urologia
researchProduct

OPKINE, a multipurpose program for kinetics

1991

The program OPKINE is presented for the study of reaction mechanisms and multicomponent analysis in dynamic conditions. This program is written in FORTRAN-77 for IBM 30/90 and VAX 8300 computers, and permits the simultaneous evaluation of both rate constants and initial reagent concentrations or, alternatively, rate constants and sensitivities. Up to 20 kinetic curves, with up to 400 points each, can be treated to evaluate up to 40 parameters. Integration of the system of differential equations is performed by means of the Runge–Kutta–Fehlberg method. OPKINE is provided with the Simplex, and modified versions of the Davidon–Fletcher–Powell and Gauss–Newton–Marquardt optimization methods. A …

Computational MathematicsReaction rate constantSimplexSystem of differential equationsComputer scienceReagentMonte Carlo methodKineticsOptimization methodsApplied mathematicsGeneral ChemistryKinetic energyAlgorithmJournal of Computational Chemistry
researchProduct

Kinetics of the permanganate oxidation of formic acid in aqueous solution

1987

The kinetics of the permanganate oxidation of formic acid in aqueous perchloric acid at 30°C were examined by the spectrophotometric method. The chemical reaction 2MnO + 3HCOOH + 2H+ 2MnO2 + 3CO2 + 4H2O, appears to proceed via several parallel reactions. The overall rate equation has been obtained by using statistical multilinear regression analysis of the 660 cases studied, and the presence in the rate equation of two new terms in relation to previous studies shows that both permanganate autocatalytic effects and acid media inhibition must be taken into account when the reaction proceeds at constant ionic strength.

Aqueous solutionFormic acidOrganic ChemistryPermanganateInorganic chemistryRate equationBiochemistryChemical reactionInorganic ChemistryAutocatalysischemistry.chemical_compoundchemistryIonic strengthPerchloric acidPhysical and Theoretical ChemistryInternational Journal of Chemical Kinetics
researchProduct

Factores de riesgo de enfermedad residual en la re-RTU en una gran cohorte de pacientes con enfermedad T1G3

2021

Resumen Introduccion y objetivos Los objetivos de la reseccion transuretral (RTU) del tumor vesical son la reseccion completa de las lesiones y la realizacion de un diagnostico correcto con el objetivo de estadificar adecuadamente al paciente. Es bien sabido que la presencia de musculo detrusor en el especimen es un requisito previo para minimizar el riesgo de infraestadificacion. La persistencia de enfermedad tras la reseccion de los tumores vesicales no es infrecuente, y es la razon por la que las guias europeas recomiendan una re-reseccion transuretral (re-RTU) para todos los tumores T1. Recientemente se ha publicado que, en los casos con inclusion de musculo en el especimen, la re-RTU n…

Gynecology03 medical and health sciencesmedicine.medical_specialty0302 clinical medicinebusiness.industryUrology030232 urology & nephrologymedicinebusinessActas Urológicas Españolas
researchProduct

Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy

2018

PURPOSE: To evaluate the oncological impact of postponing radical cystectomy (RC) to allow further conservative therapies prior to progression in a large multicentre retrospective cohort of T1-HG/G3 patients initially treated with BCG. METHODS: According to the time of RC, the population was divided into 3 groups: patients who did not progress to muscle-invasive disease, patients who progressed before radical cystectomy and patients who experienced progression at the time of radical cystectomy. Clinical and pathological outcomes were compared across the three groups. RESULTS: Of 2451 patients, 509 (20.8%) underwent RC. Patients with tumors > 3 cm or with CIS had earlier cystectomies (HR = 1…

NephrologyMalemedicine.medical_treatment030232 urology & nephrologyKaplan-Meier EstimateSettore MED/24 - UrologiaCohort Studies0302 clinical medicineRetrospective StudieMultivariate AnalysiOutcomeeducation.field_of_studyHigh riskBladder cancerMiddle AgedPrognosisEditorialTreatment OutcomeLocal030220 oncology & carcinogenesisBCG VaccineFemaleSurvival AnalysiBladder cancer; Cystectomy; Extravesical disease; High risk; Outcomes; T1G3; UrologyHumanmedicine.medical_specialtyPrognosiUrologyPopulationUrologyOutcomesT1G3CystectomyRisk AssessmentDisease-Free SurvivalCystectomy03 medical and health sciencesAll institutes and research themes of the Radboud University Medical CenterInternal medicineUrological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15]medicineHumansNeoplasm InvasivenesseducationSurvival analysisProportional Hazards ModelsRetrospective StudiesAgedNeoplasm StagingNeoplasm InvasiveneCarcinoma Transitional CellBladder cancerbusiness.industryProportional hazards modelBladder cancer; Cystectomy; Extravesical disease; High risk; Outcomes; T1G3; Aged; BCG Vaccine; Carcinoma Transitional Cell; Cohort Studies; Cystectomy; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Recurrence Local; Neoplasm Staging; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Survival Analysis; Treatment Outcome; Urinary Bladder NeoplasmsCarcinomaRetrospective cohort studymedicine.diseaseSurvival AnalysisNeoplasm RecurrenceUrinary Bladder NeoplasmsConcomitantMultivariate AnalysisProportional Hazards ModelTransitional CellCohort StudieNeoplasm Recurrence LocalbusinessExtravesical disease
researchProduct

Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients

2021

Item does not contain fulltext Introduction and objectives: The goals of transurethral resection of a bladder tumor (TUR) are to completely resect the lesions and to make a correct diagnosis in order to adequately stage the patient. It is well known that the presence of detrusor muscle in the specimen is a prerequisite to minimize the risk of under staging. Persistent disease after resection of bladder tumors is not uncommon and is the reason why the European Guidelines recommended a re-TUR for all T1 tumors. It was recently published that when there is muscle in the specimen, re-TUR does not influence progression or cancer specific survival. We present here the patient and tumor factors th…

Detrusor musclemedicine.medical_specialty030232 urology & nephrologyUrologyDiseaseLogistic regression03 medical and health sciencesTumor Status0302 clinical medicineRe-transurethral resection of the bladderRecurrenceRisk FactorsUrological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15]MedicineHumansStage (cooking)Non-muscle invasive bladder cancer; Re-transurethral resection of the bladder; Residual disease; Recurrence; ProgressionNeoplasm StagingRetrospective StudiesUnivariate analysisCarcinoma Transitional CellProgressionbusiness.industryRetrospective cohort studyGeneral MedicineResidual diseaseReconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10]Settore MED/24medicine.anatomical_structureUrinary Bladder NeoplasmsConcomitantNon-muscle invasive bladder cancerbusiness
researchProduct

ASSOCIATION OF AN ORGAN TRANSPLANT-BASED APPROACH WITH A DRAMATIC REDUCTION IN POSTOPERATIVE COMPLICATIONS FOLLOWING RADICAL NEPHRECTOMY AND TUMOR TH…

2019

Objectives: Our aim was to determine whether using an organ transplant-based(TB) approach reduces postoperative complications(PCs) following radical nephrectomy(RN) and tumor thrombectomy(TT) in renal cell carcinoma(RCC) patients with level II-IV thrombi. Methods: A total of 390(292 non-TB/98 TB) IRCC-VT Consortium patients who received no preoperative embolization/IVC filter were included. Stepwise linear/logistic regression analyses were performed to determine significant multivariable predictors of intraoperative estimated blood loss(IEBL), number blood transfusions received, and overall/major PC development within 30days following surgery. Propensity to receive the TB approach was contr…

MaleKidney DiseaseVena Cavamedicine.medical_treatment030232 urology & nephrologyLogistic regressionNephrectomyOrgan transplantation0302 clinical medicinePostoperative ComplicationsRenal cell carcinomaInferior vena cavaCancerThrombectomyGeneral MedicineMiddle AgedNephrectomyRenal cell carcinomaKidney NeoplasmsOncologymedicine.vein030220 oncology & carcinogenesisFemaleInferior vena cava; Postoperative complications; Renal cell carcinoma; Surgical technique; Tumor thrombus6.4 SurgeryInferiormedicine.medical_specialtyOncology and CarcinogenesisUrologyIvc filterVena Cava InferiorInferior vena cavaArticle03 medical and health sciencesPostoperative complicationsRare DiseasesBlood lossmedicineHumansBlood TransfusionOncology & CarcinogenesisCarcinoma Renal CellRetrospective Studiesbusiness.industryCarcinomaRenal CellEvaluation of treatments and therapeutic interventionsSurgical techniqueThrombosismedicine.diseasePostoperative complicationTumor thrombusPropensity score matchingSurgerybusinessFollow-Up Studies
researchProduct

Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as pr…

2018

PURPOSE: The goals of transurethral resection of a bladder tumor (TUR) are to completely resect the lesions and to make a correct diagnosis to adequately stage and treat the patient. Persistent disease after TUR is not uncommon and is why re-TUR is recommended in T1G3 patients. When there is T1 tumor in the re-TUR specimen, very high risks of progression (82%) have been reported. We analyze the risks of recurrence, progression to muscle-invasive disease and cancer-specific mortality (CSM) according to tumor stage at re-TUR in T1G3 patients treated with BCG. METHODS: In our retrospective cohort of 2451 T1G3 patients, 934 patients (38.1%) underwent re-TUR. 667 patients had residual disease (7…

NephrologyMalemedicine.medical_treatment030232 urology & nephrologyNon-muscle invasive bladder cancer · Re-transurethral resection of the bladder · Recurrence · ProgressionSettore MED/24 - Urologia0302 clinical medicineRetrospective StudieRe-transurethral resection of the bladderRecurrenceImmunologicCause of DeathCumulative incidenceStage (cooking)Cause of deathProgressionIntravesicalAdministration IntravesicalLocal030220 oncology & carcinogenesisAdministrationBCG VaccineDisease ProgressionFemaleNon-muscle invasive bladder cancerHumanReoperationmedicine.medical_specialtyUrologyUrologyCystectomyArticleFollow-Up StudieCystectomy03 medical and health sciencesAll institutes and research themes of the Radboud University Medical CenterAdjuvants ImmunologicInternal medicineUrological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15]medicineHumansAdjuvantsAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesBladder cancerProportional hazards modelbusiness.industryNon-muscle invasive bladder cancer; Progression; Re-transurethral resection of the bladder; Recurrence; Adjuvants Immunologic; Administration Intravesical; Aged; BCG Vaccine; Cause of Death; Cystectomy; Disease Progression; Female; Follow-Up Studies; Humans; Male; Neoplasm Recurrence Local; Neoplasm Staging; Proportional Hazards Models; Reoperation; Retrospective Studies; Urinary Bladder NeoplasmsRetrospective cohort studymedicine.diseaseNeoplasm RecurrenceUrinary Bladder NeoplasmsProportional Hazards ModelNeoplasm Recurrence LocalbusinessFollow-Up Studies
researchProduct

Clinical intervals and diagnostic characteristics in a cohort of prostate cancer patients in Spain: a multicentre observational study

2015

BACKGROUND: Little is known about the healthcare process for patients with prostate cancer, mainly because hospital-based data are not routinely published. The main objective of this study was to determine the clinical characteristics of prostate cancer patients, the, diagnostic process and the factors that might influence intervals from consultation to diagnosis and from diagnosis to treatment. METHODS: We conducted a multicentre, cohort study in seven hospitals in Spain. Patients' characteristics and diagnostic and therapeutic variables were obtained from hospital records and patients' structured interviews from October 2010 to September 2011. We used a multilevel logistic regression mode…

MalePròstata -- Càncer -- DiagnosiEspaña:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Cohort StudiesProstate cancerInterquartile rangePrevalence:Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms Glandular and Epithelial::Carcinoma::Adenocarcinoma [Medical Subject Headings]UrologiaStage (cooking)MasculinoProspective cohort studyEarly Detection of Cancer:Geographicals::Geographic Locations::Europe::Spain [Medical Subject Headings]:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Neoplasm Grading [Medical Subject Headings]General MedicineHumanosCohortCritical PathwaysMale urogenital diseasesEducational StatusProstatic neoplasmsCohort studyCohort studyEmploymentmedicine.medical_specialtyUrology:Check Tags::Male [Medical Subject Headings]Clasificación del TumorNeoplasias de la PróstataAdenocarcinomaMulticentre studyTime-to-Treatment:Diseases::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms Male::Prostatic Neoplasms [Medical Subject Headings]Age DistributionInternal medicinemedicineHumansProspective studyAgedGynecologybusiness.industryResearchMale urogenital diseasesCancerProstatic NeoplasmsOdds ratiomedicine.diseaseReproductive MedicineSpainbusiness
researchProduct